Clinical Trial: Efficacy and Feasibility of BurstDR SCS in Painful Diabetic Neuropathy

U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07250828) titled 'Efficacy and Feasibility of BurstDR SCS in Painful Diabetic Neuropathy' on Nov. 18.

Brief Summary: This prospective, single-arm clinical study evaluates the therapeutic efficacy and feasibility of BurstDR spinal cord stimulation (SCS) using Abbott's Proclaim XR and Eterna systems in patients with painful diabetic neuropathy (PDN). Adults with confirmed PDN will undergo a one-week temporary SCS trial, and those achieving meaningful improvement (>=50% reduction in average pain on the Visual Analog Scale) will proceed to permanent implantation. Outcomes will be assessed at baseline, end of trial, and at 1-, 3-, and 6-month follow-up vi...